Operaciones Kaleido Biosciences, Inc. - KLDO CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.05 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Estadísticas clave
| Cierre previo* | 0.39 |
| Abrir* | 0.4 |
| Cambio de 1 año* | 2.56% |
| Rango del día* | 0.38 - 0.45 |
| Rango de 52 semanas | 0.00-1.92 |
| Volumen medio (10 días) | 26.79K |
| Volumen medio (3 meses) | 306.37K |
| Capitalización de mercado | 8,520.00 |
| Ratio P/E | -100.00K |
| Acciones en circulación | 42.62M |
| Ingresos | 1.10M |
| EPS | -2.16 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 0.47 |
| Próxima fecha de resultados | Mar 23, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Apr 14, 2022 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
| Apr 13, 2022 | 0.39 | 0.00 | 0.00% | 0.39 | 0.47 | 0.38 |
| Apr 8, 2022 | 0.40 | -0.24 | -37.50% | 0.64 | 0.64 | 0.38 |
| Apr 7, 2022 | 1.46 | -0.01 | -0.68% | 1.47 | 1.55 | 1.42 |
| Apr 6, 2022 | 1.46 | -0.02 | -1.35% | 1.48 | 1.48 | 1.42 |
| Apr 5, 2022 | 1.50 | -0.09 | -5.66% | 1.59 | 1.62 | 1.48 |
| Apr 4, 2022 | 1.59 | -0.14 | -8.09% | 1.73 | 1.73 | 1.54 |
| Apr 1, 2022 | 1.68 | 0.06 | 3.70% | 1.62 | 1.70 | 1.58 |
| Mar 31, 2022 | 1.60 | -0.08 | -4.76% | 1.68 | 1.72 | 1.55 |
| Mar 30, 2022 | 1.69 | -0.14 | -7.65% | 1.83 | 1.83 | 1.69 |
| Mar 29, 2022 | 1.70 | 0.02 | 1.19% | 1.68 | 1.77 | 1.60 |
| Mar 28, 2022 | 1.60 | -0.13 | -7.51% | 1.73 | 1.73 | 1.50 |
| Mar 25, 2022 | 1.64 | -0.10 | -5.75% | 1.74 | 1.74 | 1.63 |
| Mar 24, 2022 | 1.74 | 0.00 | 0.00% | 1.74 | 1.76 | 1.68 |
| Mar 23, 2022 | 1.74 | 0.01 | 0.58% | 1.73 | 1.81 | 1.73 |
| Mar 22, 2022 | 1.75 | 0.10 | 6.06% | 1.65 | 1.75 | 1.65 |
| Mar 21, 2022 | 1.63 | -0.05 | -2.98% | 1.68 | 1.68 | 1.55 |
| Mar 18, 2022 | 1.67 | 0.14 | 9.15% | 1.53 | 1.71 | 1.53 |
| Mar 17, 2022 | 1.56 | 0.14 | 9.86% | 1.42 | 1.57 | 1.42 |
| Mar 16, 2022 | 1.42 | 0.04 | 2.90% | 1.38 | 1.42 | 1.31 |
Kaleido Biosciences, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Ingresos totales | 1.104 | 0.975 | 0 | 0 | 0 |
| Gastos totales de explotación | 88.771 | 79.849 | 87.24 | 60.683 | 27.03 |
| Gastos de venta/general/administración Gastos, total | 20.968 | 23.882 | 22.428 | 18.621 | 6.038 |
| Investigación y desarrollo | 67.803 | 55.967 | 64.232 | 42.062 | 20.992 |
| Ingresos de explotación | -87.667 | -78.874 | -87.24 | -60.683 | -27.03 |
| Ingresos por intereses (gastos), netos No operativos | -2.766 | -2.553 | 0.968 | -0.805 | -0.512 |
| Otros, netos | 0.145 | -0.193 | -0.059 | -0.256 | -0.017 |
| Ingresos netos antes de impuestos | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Ingresos netos después de impuestos | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Beneficio neto antes de partidas extra. Elementos | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Ingresos netos | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Beneficio neto diluido | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Promedio ponderado de acciones diluidas | 41.86 | 33.4502 | 25.7033 | 29.3948 | 29.3948 |
| BPA diluido sin partidas extraordinarias | -2.1569 | -2.44004 | -3.35876 | -2.10051 | -0.93755 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| BPA normalizado diluido | -2.1569 | -2.44004 | -3.33619 | -2.10051 | -0.93755 |
| Gastos (ingresos) extraordinarios | 0 | 0.58 | |||
| Ingresos | 1.104 | 0.975 |
| Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
|---|---|---|---|---|---|
| Ingresos totales | 0.492 | 0.104 | 0.211 | 0.297 | 0.243 |
| Ingresos | 0.492 | 0.104 | 0.211 | 0.297 | 0.243 |
| Gastos totales de explotación | 20.191 | 22.517 | 23.418 | 22.645 | 19.543 |
| Gastos de venta/general/administración Gastos, total | 4.617 | 5.106 | 5.785 | 5.46 | 5.205 |
| Investigación y desarrollo | 15.574 | 17.411 | 17.633 | 17.185 | 14.338 |
| Gastos (ingresos) extraordinarios | 0 | ||||
| Ingresos de explotación | -19.699 | -22.413 | -23.207 | -22.348 | -19.3 |
| Ingresos por intereses (gastos), netos No operativos | -0.705 | -0.692 | -0.681 | -0.688 | -0.713 |
| Otros, netos | 0.132 | 0.02 | -0.001 | -0.006 | -0.003 |
| Ingresos netos antes de impuestos | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Ingresos netos después de impuestos | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Beneficio neto antes de partidas extra. Elementos | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Ingresos netos | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Beneficio neto diluido | -20.272 | -23.085 | -23.889 | -23.042 | -20.016 |
| Promedio ponderado de acciones diluidas | 42.5995 | 42.5776 | 42.5386 | 39.6926 | 35.9841 |
| BPA diluido sin partidas extraordinarias | -0.47587 | -0.54219 | -0.56158 | -0.58051 | -0.55625 |
| BPA normalizado diluido | -0.47587 | -0.54219 | -0.56158 | -0.58051 | -0.55625 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 42.311 | 48.721 | 73.279 | 76.243 | 28.551 |
| Efectivo e inversiones a corto plazo | 38.474 | 46.222 | 71.241 | 76.086 | 28.456 |
| Efectivo y Equivalentes | 38.474 | 46.222 | 71.241 | 76.086 | 28.456 |
| Total deudores, neto | 0.005 | 0.045 | |||
| Prepaid Expenses | 3.583 | 2.499 | 2.038 | 0.152 | 0.05 |
| Total Assets | 50.137 | 59.344 | 82.306 | 85.325 | 30.747 |
| Property/Plant/Equipment, Total - Net | 5.665 | 8.462 | 6.742 | 4.693 | 1.975 |
| Property/Plant/Equipment, Total - Gross | 11.136 | 11.955 | 9.281 | 5.914 | 2.406 |
| Accumulated Depreciation, Total | -5.471 | -3.493 | -2.539 | -1.221 | -0.431 |
| Other Long Term Assets, Total | 2.161 | 2.161 | 2.285 | 4.389 | 0.221 |
| Total Current Liabilities | 29.682 | 16.659 | 10.377 | 11.301 | 3.854 |
| Accounts Payable | 5.67 | 5.389 | 2.016 | 3.442 | 0.864 |
| Accrued Expenses | 6.686 | 7.356 | 7.086 | 7.406 | 2.615 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 16.144 | 2.634 | 0.068 | 0.091 | 0.104 |
| Other Current Liabilities, Total | 1.182 | 1.28 | 1.207 | 0.362 | 0.271 |
| Total Liabilities | 39.53 | 38.848 | 33.423 | 28.343 | 21.932 |
| Total Long Term Debt | 5.55 | 18.375 | 20.391 | 14.831 | 14.81 |
| Long Term Debt | 5.55 | 18.375 | 20.391 | 14.831 | 14.81 |
| Other Liabilities, Total | 4.298 | 3.814 | 2.655 | 2.211 | 3.268 |
| Total Equity | 10.607 | 20.496 | 48.883 | 56.982 | 8.815 |
| Preferred Stock - Non Redeemable, Net | 153.226 | 52.494 | |||
| Common Stock | 0.043 | 0.036 | 0.03 | 0.006 | 0.005 |
| Additional Paid-In Capital | 375.031 | 294.639 | 241.412 | 9.978 | 0.8 |
| Retained Earnings (Accumulated Deficit) | -364.467 | -274.179 | -192.559 | -106.228 | -44.484 |
| Total Liabilities & Shareholders’ Equity | 50.137 | 59.344 | 82.306 | 85.325 | 30.747 |
| Total Common Shares Outstanding | 42.596 | 36.0228 | 30.1278 | 29.3948 | 29.3948 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Other Current Assets, Total | 0.254 |
| Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 42.311 | 58.304 | 74.603 | 95.032 | 48.721 |
| Efectivo e inversiones a corto plazo | 38.474 | 55.657 | 71.979 | 92.362 | 46.222 |
| Efectivo y Equivalentes | 38.474 | 55.657 | 71.979 | 92.362 | 46.222 |
| Prepaid Expenses | 3.583 | 2.647 | 2.624 | 2.67 | 2.499 |
| Total Assets | 50.137 | 67.804 | 84.29 | 105.026 | 59.344 |
| Property/Plant/Equipment, Total - Net | 5.665 | 7.339 | 7.526 | 7.833 | 8.462 |
| Property/Plant/Equipment, Total - Gross | 11.136 | 12.482 | 12.165 | 11.889 | 11.955 |
| Accumulated Depreciation, Total | -5.471 | -5.143 | -4.639 | -4.056 | -3.493 |
| Other Long Term Assets, Total | 2.161 | 2.161 | 2.161 | 2.161 | 2.161 |
| Total Current Liabilities | 29.682 | 19.261 | 12.269 | 12.873 | 16.659 |
| Accounts Payable | 5.67 | 3.559 | 2.695 | 2.412 | 5.389 |
| Accrued Expenses | 6.686 | 8.681 | 5.014 | 4.403 | 7.356 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 16.144 | 6.384 | 3.667 | 4.759 | 2.634 |
| Other Current Liabilities, Total | 1.182 | 0.637 | 0.893 | 1.299 | 1.28 |
| Total Liabilities | 39.53 | 38.604 | 34.024 | 33.252 | 38.848 |
| Total Long Term Debt | 5.55 | 15.132 | 17.677 | 16.433 | 18.375 |
| Long Term Debt | 5.55 | 15.132 | 17.677 | 16.433 | 18.375 |
| Other Liabilities, Total | 4.298 | 4.211 | 4.078 | 3.946 | 3.814 |
| Total Equity | 10.607 | 29.2 | 50.266 | 71.774 | 20.496 |
| Common Stock | 0.043 | 0.043 | 0.043 | 0.042 | 0.036 |
| Additional Paid-In Capital | 375.031 | 373.352 | 371.333 | 368.953 | 294.639 |
| Retained Earnings (Accumulated Deficit) | -364.467 | -344.195 | -321.11 | -297.221 | -274.179 |
| Total Liabilities & Shareholders’ Equity | 50.137 | 67.804 | 84.29 | 105.026 | 59.344 |
| Total Common Shares Outstanding | 42.596 | 42.5801 | 42.5714 | 42.4832 | 36.0228 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Other Current Assets, Total | 0.254 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -90.288 | -81.62 | -86.331 | -61.744 | -27.559 |
| Efectivo de actividades de explotación | -77.094 | -61.518 | -75.796 | -46.316 | -22.495 |
| Efectivo de actividades de explotación | 2.358 | 1.823 | 1.318 | 0.792 | 0.316 |
| Partidas no monetarias | 11.099 | 13.728 | 10.433 | 8.14 | 0.738 |
| Intereses pagados en efectivo | 2.133 | 1.925 | 0.881 | 0.943 | 0.343 |
| Cambios en el capital circulante | -0.263 | 4.551 | -1.216 | 6.496 | 4.01 |
| Efectivo de actividades de inversión | -0.691 | -4.024 | -3.586 | -3.002 | -1.406 |
| Gastos de capital | -1.129 | -4.024 | -3.586 | -3.002 | -1.406 |
| Efectivo procedente de actividades de financiación | 70.037 | 40.399 | 74.642 | 98.907 | 49.736 |
| Elementos de flujo de caja de financiación | -0.359 | -0.079 | -1.158 | -1.84 | 0 |
| Emisión (retiro) de acciones, neto | 70.396 | 40.546 | 68.391 | 100.852 | 39.86 |
| Emisión (amortización) de deuda, neta | 0 | -0.068 | 7.409 | -0.105 | 9.876 |
| Variación neta de la tesorería | -7.748 | -25.143 | -4.74 | 49.589 | 25.835 |
| Otras partidas de flujo de caja de inversión, total | 0.438 |
| Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -90.288 | -70.016 | -46.931 | -23.042 | -81.62 |
| Cash From Operating Activities | -77.094 | -59.934 | -44.057 | -23.974 | -61.518 |
| Cash From Operating Activities | 2.358 | 1.754 | 1.16 | 0.577 | 1.823 |
| Non-Cash Items | 11.099 | 9.331 | 7.146 | 4.603 | 13.728 |
| Cash Interest Paid | 2.133 | 1.601 | 1.064 | 0.526 | 1.925 |
| Changes in Working Capital | -0.263 | -1.003 | -5.432 | -6.112 | 4.551 |
| Cash From Investing Activities | -0.691 | -0.693 | -0.262 | -0.03 | -4.024 |
| Capital Expenditures | -1.129 | -0.693 | -0.262 | -0.03 | -4.024 |
| Cash From Financing Activities | 70.037 | 70.062 | 70.076 | 70.144 | 40.399 |
| Financing Cash Flow Items | -0.359 | -0.329 | -0.31 | -0.186 | -0.079 |
| Issuance (Retirement) of Stock, Net | 70.396 | 70.391 | 70.386 | 70.33 | 40.546 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | -0.068 | |
| Net Change in Cash | -7.748 | 9.435 | 25.757 | 46.14 | -25.143 |
| Other Investing Cash Flow Items, Total | 0.438 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Menichella (Daniel L.) | Individual Investor | 0.2996 | 127700 | 107700 | 2022-03-31 | MED |
| Duke (William E. Jr.) | Individual Investor | 0.1598 | 68115 | 68115 | 2022-03-31 | LOW |
| Korn (Jerald) | Individual Investor | 0.1215 | 51803 | 51803 | 2022-03-31 | |
| Melas-Kyriazi (Theo) | Individual Investor | 0.0782 | 33333 | 0 | 2022-03-31 | LOW |
| Quinn (Anthony G) | Individual Investor | 0.0741 | 31603 | 0 | 2022-03-31 | LOW |
| Northern Trust Global Investments | Investment Advisor | 0.0334 | 14235 | 14235 | 2022-12-31 | LOW |
| DWS Investments UK Limited | Investment Advisor | 0.0244 | 10387 | 0 | 2023-02-28 | MED |
| Amalgamated Financial Corp. | Investment Advisor | 0.0077 | 3266 | 3266 | 2022-03-31 | |
| Mackenzie Financial Corporation | Investment Advisor/Hedge Fund | 0.0027 | 1139 | -148 | 2022-09-30 | LOW |
| Westfield Capital Management Company, L.P. | Investment Advisor/Hedge Fund | 0.002 | 854 | 0 | 2021-09-30 | LOW |
| Carroll Financial Associates, Inc. | Investment Advisor | 0.0008 | 339 | 0 | 2021-12-31 |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Kaleido Biosciences, Inc. Company profile
Sobre Kaleido Biosciences Inc
Kaleido Biosciences, Inc. es una empresa sanitaria en fase clínica centrada en aprovechar el potencial del órgano del microbioma para tratar enfermedades y mejorar la salud humana. Sus terapias metabólicas del microbioma (MMT) están diseñadas para impulsar la función y la distribución de los microbios existentes con el fin de disminuir o aumentar la producción de metabolitos a ciertas bacterias en la comunidad del microbioma. La empresa también está avanzando en una amplia cartera de candidatos a MMT con el potencial de abordar una variedad de enfermedades y afecciones con necesidades insatisfechas de los pacientes. La empresa utiliza su plataforma de descubrimiento y desarrollo para estudiar los MMT en muestras del microbioma, con el fin de hacer avanzar rápidamente los candidatos a MMT hacia estudios clínicos en sujetos sanos y pacientes. Su KB195 es el principal candidato a MMT para su desarrollo en el tratamiento de pacientes con trastornos del ciclo de la urea. La empresa está llevando a cabo un ensayo clínico de fase II en el marco de una solicitud de nuevo fármaco en investigación (IND).
| Industry: | Biotechnology & Medical Research (NEC) |
18 Crosby Dr
BEDFORD
MASSACHUSETTS 01730-1402
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com